MX362702B - Compuesto de semifluorocarbono que contiene agente de contraste. - Google Patents
Compuesto de semifluorocarbono que contiene agente de contraste.Info
- Publication number
- MX362702B MX362702B MX2015013746A MX2015013746A MX362702B MX 362702 B MX362702 B MX 362702B MX 2015013746 A MX2015013746 A MX 2015013746A MX 2015013746 A MX2015013746 A MX 2015013746A MX 362702 B MX362702 B MX 362702B
- Authority
- MX
- Mexico
- Prior art keywords
- semifluorocarbon
- compound containing
- contrast agent
- containing contrast
- integer ranging
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000002872 contrast media Substances 0.000 title 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- High Energy & Nuclear Physics (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Signal Processing (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmacology & Pharmacy (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
La presente invención se refiere a una emulsión acuosa que comprende a) un compuesto semifluorado de fórmula I: CF3- (CF2)X-(CH2)-CH3 (I) donde x es un número entero que oscila de 1 a 8 e y es un número entero que oscila de 2 a 10, b) un triglicérido que es miscible con el compuesto semifluorado a 20°C; y c) un emulsionante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13160868.9A EP2783703A1 (en) | 2013-03-25 | 2013-03-25 | Semifluorocarbon compound containing contrast agent |
PCT/EP2014/055398 WO2014154531A1 (en) | 2013-03-25 | 2014-03-18 | Semifluorocarbon compound containing contrast agent |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015013746A MX2015013746A (es) | 2016-02-26 |
MX362702B true MX362702B (es) | 2019-02-01 |
Family
ID=47913282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013746A MX362702B (es) | 2013-03-25 | 2014-03-18 | Compuesto de semifluorocarbono que contiene agente de contraste. |
Country Status (17)
Country | Link |
---|---|
US (2) | US20160000941A1 (es) |
EP (2) | EP2783703A1 (es) |
JP (1) | JP6356780B2 (es) |
KR (1) | KR102210774B1 (es) |
CN (1) | CN105142681B (es) |
BR (1) | BR112015017572A2 (es) |
CA (1) | CA2893799C (es) |
DK (1) | DK2978455T3 (es) |
ES (1) | ES2616884T3 (es) |
HU (1) | HUE030818T2 (es) |
IL (1) | IL239203A (es) |
MX (1) | MX362702B (es) |
PL (1) | PL2978455T3 (es) |
PT (1) | PT2978455T (es) |
RU (1) | RU2672588C2 (es) |
TW (1) | TWI652069B (es) |
WO (1) | WO2014154531A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2788060C (en) | 2010-03-17 | 2017-07-11 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
CN107397718A (zh) | 2011-05-25 | 2017-11-28 | 诺瓦利克有限责任公司 | 基于半氟化烷烃类的外用药物组合物 |
DK2806886T3 (en) | 2012-01-23 | 2017-06-06 | Novaliq Gmbh | STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES |
DK2895144T3 (en) | 2012-09-12 | 2017-03-06 | Novaliq Gmbh | SEMIFLUORED ALKAN COMPOSITIONS |
EP2895158B1 (en) | 2012-09-12 | 2019-11-20 | Novaliq GmbH | Compositions comprising mixtures of semifluorinated alkanes |
CN114028560A (zh) | 2013-07-23 | 2022-02-11 | 诺瓦利克有限责任公司 | 稳定的抗体组合物 |
JP6602964B2 (ja) | 2015-09-30 | 2019-11-06 | ノバリック ゲーエムベーハー | 半フッ素化化合物およびその組成物 |
CN108349855B (zh) | 2015-09-30 | 2021-07-20 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
EP3203256A1 (en) * | 2016-02-02 | 2017-08-09 | B. Braun Melsungen AG | Calibration of mri systems using pre-defined concentrations of 19f isotopes as reference |
ES2763121T3 (es) | 2016-06-23 | 2020-05-27 | Novaliq Gmbh | Método de administración tópica |
WO2018054932A1 (en) | 2016-09-22 | 2018-03-29 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
KR20190057338A (ko) | 2016-09-23 | 2019-05-28 | 노바리크 게엠베하 | 시클로스포린을 포함하는 안과 조성물 |
ES2957559T3 (es) | 2017-04-21 | 2024-01-22 | Dermaliq Therapeutics Inc | Composiciones de yodo |
WO2018202835A1 (en) | 2017-05-05 | 2018-11-08 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
EP3621601A1 (en) | 2017-05-12 | 2020-03-18 | Novaliq GmbH | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
EP3687496A1 (en) | 2017-09-27 | 2020-08-05 | Novaliq GmbH | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
CN112135603B (zh) | 2018-03-02 | 2024-04-16 | 诺瓦利克有限责任公司 | 包含奈必洛尔的药物组合物 |
JP7360452B2 (ja) | 2018-09-27 | 2023-10-12 | ダーマリック セラピューティクス, インコーポレーテッド | 脂質バリアの修復 |
AU2019345929B2 (en) | 2018-09-27 | 2022-02-03 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
CN112823020A (zh) | 2018-10-12 | 2021-05-18 | 诺瓦利克有限责任公司 | 用于治疗干眼病的眼用组合物 |
RU2723391C1 (ru) * | 2019-09-19 | 2020-06-11 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Способ определения тромбоза ушка левого предсердия по данным контрастной трансторакальной эхокардиографии |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2054658T3 (es) | 1986-01-24 | 1994-08-16 | Childrens Hosp Medical Center | Metodo para la preparacion de una emulsion fisiologicamente aceptable. |
US5171755A (en) * | 1988-04-29 | 1992-12-15 | Hemagen/Pfc | Emulsions of highly fluorinated organic compounds |
DE4405627A1 (de) * | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
US7220401B2 (en) * | 1999-09-24 | 2007-05-22 | Barnes-Jewish Hospital | Blood clot-targeted nanoparticles |
IL163937A0 (en) | 2002-03-07 | 2005-12-18 | Univ Carnegie Mellon | Contrast agents for magnetic resonance imaging andmethods realted thereto |
EP2319544A1 (en) * | 2004-01-16 | 2011-05-11 | Carnegie Mellon University | Cellular labeling for nuclear magnetic resonance techniques |
RU2262920C1 (ru) * | 2004-09-28 | 2005-10-27 | Открытое Акционерное Общество "Фаберлик" | Водная эмульсия перфторсоединений для косметических и/или дерматологических препаратов и способ ее получения |
EP1885243A4 (en) | 2005-05-11 | 2014-05-21 | Univ Minnesota | METHODS AND DEVICE FOR REPRESENTING MAGNETIC INDUCTION |
DE102007015598A1 (de) | 2007-03-29 | 2008-10-02 | Heinrich-Heine-Universität Düsseldorf | Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren |
CA2788060C (en) * | 2010-03-17 | 2017-07-11 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
JP6073244B2 (ja) | 2011-01-04 | 2017-02-01 | ノバリック ゲーエムベーハー | 部分フッ素化アルカンを含むo/wエマルション |
US20130280170A1 (en) * | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
-
2013
- 2013-03-25 EP EP13160868.9A patent/EP2783703A1/en not_active Withdrawn
-
2014
- 2014-03-05 TW TW103107324A patent/TWI652069B/zh active
- 2014-03-18 WO PCT/EP2014/055398 patent/WO2014154531A1/en active Application Filing
- 2014-03-18 BR BR112015017572A patent/BR112015017572A2/pt not_active Application Discontinuation
- 2014-03-18 HU HUE14710891A patent/HUE030818T2/en unknown
- 2014-03-18 PT PT147108914T patent/PT2978455T/pt unknown
- 2014-03-18 EP EP14710891.4A patent/EP2978455B1/en active Active
- 2014-03-18 RU RU2015130915A patent/RU2672588C2/ru active
- 2014-03-18 MX MX2015013746A patent/MX362702B/es active IP Right Grant
- 2014-03-18 CA CA2893799A patent/CA2893799C/en active Active
- 2014-03-18 DK DK14710891.4T patent/DK2978455T3/en active
- 2014-03-18 US US14/759,444 patent/US20160000941A1/en not_active Abandoned
- 2014-03-18 ES ES14710891.4T patent/ES2616884T3/es active Active
- 2014-03-18 PL PL14710891T patent/PL2978455T3/pl unknown
- 2014-03-18 CN CN201480016964.3A patent/CN105142681B/zh active Active
- 2014-03-18 JP JP2016504568A patent/JP6356780B2/ja active Active
- 2014-03-18 KR KR1020157026470A patent/KR102210774B1/ko active IP Right Grant
-
2015
- 2015-06-04 IL IL239203A patent/IL239203A/en active IP Right Grant
-
2023
- 2023-05-02 US US18/310,588 patent/US20230355810A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2014154531A1 (en) | 2014-10-02 |
EP2978455A1 (en) | 2016-02-03 |
TW201524521A (zh) | 2015-07-01 |
IL239203A0 (en) | 2015-07-30 |
PL2978455T3 (pl) | 2017-06-30 |
RU2015130915A3 (es) | 2018-03-19 |
US20230355810A1 (en) | 2023-11-09 |
RU2672588C2 (ru) | 2018-11-16 |
HUE030818T2 (en) | 2017-06-28 |
DK2978455T3 (en) | 2017-03-06 |
KR102210774B1 (ko) | 2021-02-02 |
JP6356780B2 (ja) | 2018-07-11 |
IL239203A (en) | 2017-03-30 |
KR20150132836A (ko) | 2015-11-26 |
CA2893799C (en) | 2021-03-09 |
JP2016515553A (ja) | 2016-05-30 |
TWI652069B (zh) | 2019-03-01 |
CN105142681B (zh) | 2019-03-12 |
RU2015130915A (ru) | 2017-04-27 |
BR112015017572A2 (pt) | 2017-07-11 |
PT2978455T (pt) | 2017-02-24 |
ES2616884T3 (es) | 2017-06-14 |
EP2978455B1 (en) | 2017-01-04 |
MX2015013746A (es) | 2016-02-26 |
EP2783703A1 (en) | 2014-10-01 |
CN105142681A (zh) | 2015-12-09 |
US20160000941A1 (en) | 2016-01-07 |
CA2893799A1 (en) | 2014-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX362702B (es) | Compuesto de semifluorocarbono que contiene agente de contraste. | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
AR104725A1 (es) | Composiciones surfactantes y detergentes que contienen glicerina etoxilada | |
IN2015MN00404A (es) | ||
EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
BR112016023676A2 (pt) | pó de sinterização com baixa pressão | |
BR112016000299A8 (pt) | composições, uso de uma composição, método para o combate dos fungos fitopatogênicos e uso dos componentes | |
EA201690473A1 (ru) | Комбинированный состав двух противовирусных соединений | |
ECSP15043280A (es) | Nuevos compuestos y composiciones para la inhibición de fasn | |
EA201591503A1 (ru) | Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина | |
PH12019501178A1 (en) | Thiopene derivatives as antiviral agents | |
BR112015020555A2 (pt) | método de alisamento de cabelo | |
MX2015008766A (es) | Compuestos cbd fluorados, composiciones y usos de los mismos. | |
PH12019501362A1 (en) | Polymorphs | |
EA201690911A1 (ru) | Соединения диметилбензойной кислоты | |
BR112016008736A2 (pt) | formulação estável de insulina glulisina | |
BR112016024238A2 (pt) | uso de composições aquosas de redução de desvio | |
PH12020550947A1 (en) | Polymorphs | |
AR101136A1 (es) | Proceso para la preparación de ácidos 3-hidroxipicolínicos | |
BR112015011351A2 (pt) | composição farmacêutica de difenidol de liberação sustentada | |
MX2015014531A (es) | Composicion que contiene una emulsion, la fase oleosa que comprende un compuesto que consiste de un elastomero de silicona y un tensioactivo, un polvo de elastomero de silicona y un polialquil (met) acrilato. | |
MX337130B (es) | Compuesto organoleptico novedoso. | |
RU2012113763A (ru) | Ненасыщенные блок-сополиэфирсульфоны |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |